Inquiry Basket
Loading ......
Creative Diagnostics Immunogenicity ELISA Kit provides a reliable and high-performance solution for detecting and quantifying immune responses in biological samples. The kits contain advanced assay designs and optimized detection systems that enable them to detect targets with high sensitivity and specificity and reproducibility. The kits receive full validation testing to verify their operational stability and measurement accuracy and reliable performance. The Immunogenicity ELISA Kits serve multiple purposes in vaccine development and therapeutic protein evaluation and immunogenicity assessment and clinical research applications for immunotherapy development and drug safety testing and diagnostic assay validation.
Creative Diagnostics offers Immunogenicity ELISA Kits for sensitive and specific detection of anti-drug antibodies (ADAs) in biological samples. The kits were developed through optimized assay design and validated quality control to provide high accuracy and reproducibility and stability. These methods are commonly applied in vaccine assessment and therapeutic protein safety assessment and biosimilar comparison studies and immunotherapy investigations. Our product advantages:
To meet the research and development needs for accurate and reliable immunogenicity assessment, we provide comprehensive Immunogenicity ELISA Kits. Our kits include pre-optimized assay designs together with validated detection systems which allow for accurate measurement of anti-drug antibodies (ADAs) in biological samples at both high sensitivity and specificity levels. The kits receive complete quality control and characterization tests to ensure both high reproducibility and stability and accuracy. The analytical validation process requires tests for sensitivity and specificity and linearity and lot-to-lot consistency to ensure reliable performance in preclinical and clinical studies. The kits find application in vaccine evaluation as well as therapeutic protein safety testing and biosimilar comparability studies and immunotherapy research. Our Immunogenicity ELISA Kits provide dependable results because they fulfill rigorous quality requirements and benefit from our extensive knowledge of immunogenicity testing methods. Our hottest immunogenicity ELISA kits:
Background:
A biotech company was developing Adalimumab therapy for autoimmune disease. The assessment of immunogenicity served as a critical tool to track anti-drug antibodies (ADAs) from preclinical animal studies through Phase I clinical trials.
Objective:
Serum sample evaluation of ADA levels requires quantitative testing methods to determine the immune response against Adalimumab accurately.
Methods:
The researchers analyzed 120 serum samples that included 60 preclinical and 60 clinical samples.
Kit: Creative Diagnostics Anti-Adalimumab ELISA Kit.
The assay used Standard ELISA with 96-well plates that were pre-coated with Adalimumab. The detection system used HRP-conjugated secondary antibodies in combination with TMB substrate. OD was read at 450 nm.
The system contains both ADA positive and negative controls.
Results:
The system began detecting ADA concentrations at levels of 10 ng/mL.
The intra-assay coefficient of variation reached 4.2% while inter-assay measurements had a coefficient of variation of 5.1%.
The product shows no reaction with proteins that are not part of the target protein.
The research showed that 18% of clinical samples showed low levels of ADAs yet preclinical samples had a 12% positive result. The system relies on data processing to determine proper medication amounts and track how the body reacts to the immune system.
Conclusion:
The Anti-Adalimumab ELISA Kit delivered a highly sensitive and specific and reproducible method for ADA detection which enabled preclinical and early clinical decision support.
Simply put, when you develop a biologic drug, the human body may recognize it as a foreign substance and produce antibodies. The testing of immunogenicity enables you to determine the level of risk while confirming the drug's safety and effectiveness.
The majority of ELISA kits identify anti-drug antibodies (ADA) which include IgG and IgM among others. The body produces these antibodies after drug exposure which can lead to reduced drug effectiveness and adverse side effects.
The ELISA kits of high quality operate at ng/mL sensitivity levels to detect antibodies. They also have high specificity and are not susceptible to interference from other proteins in the serum.
Of course!In fact, the earlier, the better. Early screening allows you to optimize your drug candidate which reduces the likelihood of immune-related issues in future clinical development stages.
Loading ......
